Iovance Biotherapeutics (IOVA) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 395.7%.
| ASSET | % RETURN |
|---|---|
Iovance Biotherapeutics (IOVA) | 395.68% |
Twist Bioscience (TWST) | 357.77% |
10X Genomics (TXG) | 347.33% |
Veradermics (MANE) | 304.09% |
Erasca (ERAS) | 304.04% |
Immunitybio (IBRX) | 286.63% |
Pulse Biosciences (PLSE) | 280.77% |
MaxLinear (MXL) | 272.8% |
CareDx (CDNA) | 266.77% |
Abcellera Biologics (ABCL) | 253.22% |
Okeanis Eco Tankers (ECO) | 243.99% |
AXT (AXTI) | 227.15% |
Kodiak Sciences (KOD) | 221.03% |
PBF Energy (PBF) | 200.18% |
Ringcentral (RNG) | 199.32% |
Oruka Therapeutics (ORKA) | 198.02% |
Spyre Therapeutics (SYRE) | 183.61% |
Penguin Solutions (PENG) | 176.26% |
International Seaways (INSW) | 170.56% |
Delek US Energy (DK) | 168.91% |
Enliven Therapeutics (ELVN) | 167.68% |
Definium Therapeutics (DFTX) | 164.3% |
Calumet Specialty Products Partners (CLMT) | 163.88% |
Iridium Communications (IRDM) | 157.27% |
Hyperliquid Strategies Inc Common Stock (PURR) | 156.94% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.